Investing.com -- Quantum BioPharma Ltd. (NASDAQ: QNTM) stock fell 5.7% after the company announced it purchased 2,000 shares ...

Biopharmaceutical company Quantum BioPharma said it has acquired 2,000 shares of specialty games and entertainment retailer GameStop in what it calls a strategic investment.

Outside the Council of the Federation and the gathering of First Ministers, public health care advocates from across Canada will be joining ...

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), a business technology solution provider specializing in AI (Artificial Intelligence) drones, Drone ...

ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company committed to discovery and development of ...

Quantum BioPharma (QNTM) announced the purchase of 2,000 shares of GameStop (GME) to hold on the Company’s balance sheet as a strategic ...

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to innovative therapies for ...

Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Quantum BioPharma is completing a non-brokered private placement of class A multiple voting shares, with a target of up to $600 million in gross proceeds, which will enhance its working capital.

Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.

Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Unbuzzd Wellness Inc. (formerly Celly Nutrition Corp.), led by industry veterans.